Adage Capital Partners GP, L.L.C.
13F filer · CIK 0001165408Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$71.3BU.S. long equity reported on 13F
Positions984163 new · 122 closed
Net flow last quarter-$2.87BBuys minus sells
Top 10 positions weight29.5%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 2026984 positions | |||||
| $4.39B | 6.16% | 0.09% | -0.7% | Q1 2013 | |
| $3.76B | 5.27% | 0.09% | -0.4% | Q1 2013 | |
| $2.45B | 3.44% | 0.09% | +0.1% | Q1 2013 | |
| $2.09B | 2.93% | 0.08% | -4.4% | Q1 2013 | |
| $1.86B | 2.61% | 0.04% | -0.2% | Q4 2015 | |
| $1.59B | 2.22% | 0.09% | +2.1% | Q1 2016 | |
| $1.49B | 2.09% | Not reported | +2.7% | Q4 2015 | |
| $1.19B | 1.67% | 0.09% | -6.5% | Q1 2013 | |
| $1.16B | 1.63% | Not reported | 0.0% | Q4 2013 | |
| $1.04B | 1.46% | 0.06% | +2.6% | Q1 2013 | |
| $871M | 1.22% | 0.08% | -24.1% | Q1 2013 | |
| $839M | 1.18% | 0.09% | +9.0% | Q1 2013 | |
| $808M | 1.13% | Not reported | -3.7% | Q1 2013 | |
| $782M | 1.10% | 0.09% | -1.1% | Q1 2013 | |
| $711M | 1.00% | 0.57% | +13.7% | Q1 2013 | |
| $652M | 0.91% | 0.11% | +4.2% | Q1 2013 | |
| $567M | 0.80% | 0.08% | -2.4% | Q1 2013 | |
| $514M | 0.72% | 0.09% | +2.4% | Q1 2013 | |
| $503M | 0.71% | 0.08% | -1.6% | Q1 2013 | |
| $461M | 0.65% | 0.12% | +16.1% | Q1 2013 | |
| $413M | 0.58% | 0.05% | -0.4% | Q1 2013 | |
| $410M | 0.58% | 0.07% | -14.8% | Q1 2013 | |
| $407M | 0.57% | 0.09% | -10.9% | Q1 2013 | |
| $402M | 0.56% | 0.09% | +8.7% | Q1 2013 | |
| $393M | 0.55% | 0.07% | +29.7% | Q1 2013 | |
| $392M | 0.55% | 0.08% | -4.9% | Q1 2013 | |
| $370M | 0.52% | 0.09% | -0.5% | Q1 2013 | |
| $370M | 0.52% | 0.09% | +1.5% | Q1 2013 | |
| $366M | 0.51% | 1.43% | -19.1% | Q2 2022 | |
| $364M | 0.51% | 0.06% | -0.6% | Q1 2013 | |
| $349M | 0.49% | 1.36% | +904.3% | Q1 2013 | |
| $340M | 0.48% | 3.64% | +24.5% | Q4 2020 | |
| $330M | 0.46% | 0.09% | -14.8% | Q3 2021 | |
| $311M | 0.44% | 0.09% | -24.7% | Q1 2013 | |
| $295M | 0.41% | 0.08% | -12.2% | Q1 2013 | |
| $286M | 0.40% | 0.09% | -31.0% | Q1 2013 | |
| $281M | 0.39% | 0.08% | -9.2% | Q1 2013 | |
| $276M | 0.39% | 0.07% | -3.7% | Q1 2013 | |
| $276M | 0.39% | 0.09% | +4.5% | Q2 2024 | |
| $275M | 0.39% | 0.91% | +69.7% | Q1 2014 | |
| $272M | 0.38% | 0.11% | +1.5% | Q2 2020 | |
| $271M | 0.38% | 0.06% | -3.8% | Q1 2013 | |
| $262M | 0.37% | 0.09% | -8.4% | Q1 2016 | |
| $262M | 0.37% | 0.08% | +2.6% | Q1 2013 | |
| $261M | 0.37% | 0.08% | -24.5% | Q1 2013 | |
| $257M | 0.36% | 0.09% | -0.8% | Q1 2013 | |
| $253M | 0.35% | 0.10% | -4.2% | Q1 2013 | |
| $251M | 0.35% | 0.09% | -0.3% | Q1 2013 | |
| $251M | 0.35% | 0.12% | -20.3% | Q2 2013 | |
| $241M | 0.34% | 0.34% | -10.3% | Q1 2013 | |
| Q1 2026Reported May 15, 2026941 positions | |||||
| $3.85B | 5.94% | 0.09% | -0.7% | Q1 2013 | |
| $3.31B | 5.11% | 0.09% | -1.4% | Q1 2013 | |
| $2.43B | 3.75% | 0.09% | -0.8% | Q1 2013 | |
| $1.91B | 2.94% | 0.09% | +1.0% | Q1 2013 | |
| $1.5B | 2.31% | 0.04% | -0.7% | Q4 2015 | |
| $1.27B | 1.96% | 0.09% | -2.6% | Q1 2016 | |
| $1.18B | 1.82% | Not reported | +2.1% | Q4 2013 | |
| $1.18B | 1.82% | Not reported | -1.8% | Q4 2015 | |
| $898M | 1.38% | 0.06% | -2.4% | Q1 2013 | |
| $880M | 1.36% | 0.10% | +15.0% | Q1 2013 | |
| $804M | 1.24% | Not reported | +2.1% | Q1 2013 | |
| $795M | 1.23% | 0.49% | -14.5% | Q1 2013 | |
| $710M | 1.10% | 0.09% | -0.5% | Q1 2013 | |
| $602M | 0.93% | 0.10% | +11.4% | Q1 2013 | |
| $533M | 0.82% | 2.74% | +148.3% | Q1 2020 | |
| $517M | 0.80% | 0.13% | +40.5% | Q1 2013 | |
| $455M | 0.70% | 0.05% | -5.5% | Q1 2013 | |
| $450M | 0.69% | 0.08% | -1.2% | Q1 2013 | |
| $407M | 0.63% | 0.12% | -0.2% | Q1 2013 | |
| $396M | 0.61% | 0.09% | +2.1% | Q1 2013 | |
| $376M | 0.58% | 0.05% | -16.6% | Q1 2013 | |
| $374M | 0.58% | 0.10% | -0.5% | Q1 2013 | |
| $359M | 0.55% | 1.93% | -36.3% | Q2 2020 | |
| $357M | 0.55% | 0.06% | -2.3% | Q1 2013 | |
| CPCNTACentessa Pharmaceuticals PLC | $355M | 0.55% | 5.77% | -20.9% | Q2 2023 |
| $354M | 0.55% | 1.78% | +19.8% | Q2 2022 | |
| $349M | 0.54% | 0.09% | -10.0% | Q1 2013 | |
| $323M | 0.50% | 0.11% | 0.0% | Q1 2013 | |
| $320M | 0.49% | 0.08% | -2.6% | Q1 2013 | |
| $314M | 0.48% | 0.10% | -10.2% | Q1 2013 | |
| $312M | 0.48% | 0.09% | -1.6% | Q1 2013 | |
| $301M | 0.46% | 0.10% | -0.6% | Q1 2013 | |
| $299M | 0.46% | 0.09% | -0.9% | Q3 2024 | |
| $294M | 0.45% | 0.10% | +16.7% | Q3 2021 | |
| $291M | 0.45% | 1.74% | -10.2% | Q4 2021 | |
| $291M | 0.45% | 0.38% | +84.9% | Q1 2013 | |
| $291M | 0.45% | 0.31% | +122.5% | Q1 2013 | |
| $289M | 0.45% | 0.09% | +11.0% | Q1 2013 | |
| CSCTRACentra Software Inc | $289M | 0.45% | Not reported | +649.0% | Q1 2013 |
| $282M | 0.44% | 0.07% | +2.6% | Q1 2013 | |
| $274M | 0.42% | 0.08% | +0.6% | Q1 2013 | |
| $272M | 0.42% | 0.10% | +23.6% | Q2 2020 | |
| $270M | 0.42% | 0.08% | -4.3% | Q1 2013 | |
| $268M | 0.41% | 0.15% | -3.3% | Q1 2013 | |
| $268M | 0.41% | 8.89% | +20.8% | Q1 2022 | |
| $263M | 0.41% | 2.93% | -15.5% | Q4 2020 | |
| $259M | 0.40% | 0.11% | +10.7% | Q1 2013 | |
| $247M | 0.38% | 0.09% | -10.3% | Q1 2013 | |
| $245M | 0.38% | 0.38% | +7.0% | Q1 2013 | |
| VEVNOMViper Energy, Inc. | $235M | 0.36% | Not reported | -12.4% | Q4 2023 |
| Q4 2025Reported Feb 17, 2026891 positions | |||||
| $4.15B | 6.28% | 0.09% | -1.1% | Q1 2013 | |
| $3.6B | 5.44% | 0.09% | -1.1% | Q1 2013 | |
| $3.21B | 4.85% | 0.09% | -2.3% | Q1 2013 | |
| $2.09B | 3.17% | 0.08% | -2.8% | Q1 2013 | |
| $1.64B | 2.49% | 0.04% | -0.7% | Q4 2015 | |
| $1.46B | 2.21% | 0.09% | +0.4% | Q1 2016 | |
| $1.33B | 2.01% | Not reported | +1.0% | Q4 2013 | |
| $1.31B | 1.98% | Not reported | -3.3% | Q4 2015 | |
| $1.11B | 1.68% | 0.07% | +0.8% | Q1 2013 | |
| $894M | 1.35% | 0.09% | +3.2% | Q1 2013 | |
| $826M | 1.25% | Not reported | -0.1% | Q1 2013 | |
| $783M | 1.18% | 0.09% | -0.4% | Q1 2013 | |
| $659M | 1.00% | 0.57% | +18.6% | Q1 2013 | |
| $529M | 0.80% | 0.08% | -1.6% | Q1 2013 | |
| $458M | 0.69% | 0.09% | -2.3% | Q1 2013 | |
| $454M | 0.69% | 3.02% | -1.9% | Q2 2020 | |
| $432M | 0.65% | 0.05% | -2.5% | Q1 2013 | |
| $417M | 0.63% | 0.06% | -2.2% | Q1 2013 | |
| $404M | 0.61% | 0.12% | -25.4% | Q1 2013 | |
| $378M | 0.57% | 0.10% | +9.0% | Q1 2013 | |
| $367M | 0.56% | 0.09% | -0.2% | Q3 2024 | |
| $365M | 0.55% | 0.11% | -8.5% | Q1 2013 | |
| $365M | 0.55% | 0.07% | +19.3% | Q1 2013 | |
| $358M | 0.54% | 0.09% | -11.1% | Q1 2013 | |
| $345M | 0.52% | 0.09% | -18.2% | Q1 2013 | |
| $336M | 0.51% | 0.09% | -0.2% | Q1 2013 | |
| $333M | 0.50% | 0.15% | +90.6% | Q1 2013 | |
| $327M | 0.49% | 0.15% | +4.7% | Q1 2013 | |
| $320M | 0.48% | 0.06% | +29.7% | Q1 2013 | |
| $317M | 0.48% | 0.10% | -5.7% | Q1 2013 | |
| $304M | 0.46% | 1.13% | -25.8% | Q1 2014 | |
| $301M | 0.46% | 0.10% | -4.7% | Q1 2013 | |
| $297M | 0.45% | 0.09% | -0.1% | Q1 2013 | |
| $285M | 0.43% | 0.10% | +19.8% | Q1 2013 | |
| $285M | 0.43% | 3.83% | -59.3% | Q4 2020 | |
| $283M | 0.43% | 0.11% | +155.1% | Q1 2013 | |
| CPCNTACentessa Pharmaceuticals PLC | $282M | 0.43% | 7.56% | +12.4% | Q2 2023 |
| $281M | 0.42% | 0.11% | -3.2% | Q1 2013 | |
| $273M | 0.41% | 0.08% | +8.4% | Q3 2021 | |
| $271M | 0.41% | 0.09% | -45.8% | Q1 2013 | |
| $262M | 0.40% | 0.09% | -3.6% | Q1 2013 | |
| $251M | 0.38% | 0.09% | -3.4% | Q1 2013 | |
| $239M | 0.36% | 0.08% | +7.7% | Q1 2013 | |
| $232M | 0.35% | 1.50% | +47.6% | Q2 2022 | |
| $230M | 0.35% | 0.36% | +52.6% | Q1 2013 | |
| $226M | 0.34% | 0.09% | -0.6% | Q1 2013 | |
| TPTERNTerns Pharmaceuticals, Inc. | $224M | 0.34% | 4.94% | +40.9% | Q2 2023 |
| $223M | 0.34% | 0.11% | +1.4% | Q1 2013 | |
| $221M | 0.33% | 0.10% | -7.6% | Q1 2013 | |
| VEVNOMViper Energy, Inc. | $221M | 0.33% | Not reported | +21.9% | Q4 2023 |
| Q3 2025Reported Nov 14, 2025864 positions | |||||
| $4.2B | 6.65% | 0.09% | -0.1% | Q1 2013 | |
| $3.51B | 5.56% | 0.09% | -1.5% | Q1 2013 | |
| $3.4B | 5.39% | 0.09% | -0.3% | Q1 2013 | |
| $2.05B | 3.24% | 0.09% | +3.0% | Q1 2013 | |
| $1.47B | 2.32% | Not reported | -0.6% | Q4 2013 | |
| $1.39B | 2.20% | 0.09% | -0.4% | Q1 2016 | |
| $1.29B | 2.04% | 0.04% | -0.6% | Q4 2015 | |
| $1.09B | 1.73% | 0.07% | -2.6% | Q1 2013 | |
| $1.05B | 1.67% | Not reported | -0.2% | Q4 2015 | |
| $827M | 1.31% | Not reported | -1.0% | Q1 2013 | |
| $769M | 1.22% | 0.09% | -2.3% | Q1 2013 | |
| $616M | 0.98% | 0.09% | -4.2% | Q1 2013 | |
| $582M | 0.92% | 0.16% | +29.2% | Q1 2013 | |
| $561M | 0.89% | 0.48% | +30.0% | Q1 2013 | |
| $523M | 0.83% | 0.08% | -6.3% | Q1 2013 | |
| $510M | 0.81% | 0.16% | Not reported | Q1 2013 | |
| $470M | 0.74% | 0.12% | -19.5% | Q1 2013 | |
| $444M | 0.70% | 0.09% | -6.0% | Q1 2013 | |
| $441M | 0.70% | 0.06% | -4.7% | Q1 2013 | |
| $427M | 0.68% | 0.10% | +14.0% | Q1 2013 | |
| $425M | 0.67% | 0.06% | +2.9% | Q1 2013 | |
| $422M | 0.67% | 3.08% | +99.4% | Q2 2020 | |
| $420M | 0.66% | 0.09% | +69.4% | Q1 2013 | |
| $410M | 0.65% | 0.05% | -13.0% | Q1 2013 | |
| $377M | 0.60% | 0.10% | -0.8% | Q1 2013 | |
| $377M | 0.60% | 0.09% | +6.2% | Q3 2024 | |
| $361M | 0.57% | 0.09% | +12.2% | Q1 2013 | |
| $350M | 0.55% | 1.53% | -11.7% | Q1 2014 | |
| $308M | 0.49% | 0.13% | +43.8% | Q1 2013 | |
| $281M | 0.44% | 0.39% | +51.4% | Q1 2013 | |
| $281M | 0.44% | 0.10% | -4.6% | Q1 2013 | |
| $261M | 0.41% | 0.14% | +65.4% | Q1 2013 | |
| $259M | 0.41% | 0.12% | +6.4% | Q1 2013 | |
| $259M | 0.41% | 0.10% | -6.5% | Q1 2013 | |
| $249M | 0.39% | 0.08% | -6.3% | Q1 2013 | |
| $246M | 0.39% | 0.08% | -0.3% | Q3 2021 | |
| CPCNTACentessa Pharmaceuticals PLC | $243M | 0.39% | 7.47% | +19.4% | Q2 2023 |
| $234M | 0.37% | 0.09% | -5.4% | Q1 2013 | |
| $231M | 0.37% | 0.05% | -41.4% | Q1 2013 | |
| $230M | 0.36% | 0.30% | +113.7% | Q1 2013 | |
| $230M | 0.36% | 0.09% | -0.7% | Q1 2013 | |
| $225M | 0.36% | 0.98% | -45.9% | Q1 2016 | |
| $224M | 0.36% | 0.09% | -0.7% | Q1 2013 | |
| $222M | 0.35% | 0.10% | +0.7% | Q1 2013 | |
| $211M | 0.33% | 0.07% | -10.4% | Q1 2013 | |
| $208M | 0.33% | 0.17% | +20.8% | Q1 2013 | |
| $197M | 0.31% | 0.10% | -0.5% | Q1 2013 | |
| $196M | 0.31% | 0.10% | -9.3% | Q1 2013 | |
| $194M | 0.31% | 1.90% | +28.7% | Q4 2021 | |
| $194M | 0.31% | 0.12% | +17.7% | Q1 2013 | |
Premium opens every quarter this fund has filed